Investors Add Cash to Boost Imprimis Drug Delivery Work

Now that its underwriter has exercised an option to purchase an additional $1.45 million in company stock, Imprimis Pharmaceuticals Inc., of Solana Beach, Calif., is well situated to move ahead with its pipeline of compounded drug formulations based on its Accudel drug delivery technology, including Impracor, a Phase III pain candidate designed to deliver ketoprofen through the skin directly to underlying tissues.